Evidence map›Paper›PMID 41392050›Full record

ArticleScientific reports2025

Development and preliminary validation of a predictive model for IgA nephropathy progression.

Jinjin Wang, Tianmu Chen, Yan Fu, Tianqi Zhu, Yaning Feng, Yuxi Feng, Xuan Zhang, Yi Cai, Li Gao, Yongqiang Lin and 2 more

Abstract readValidation Study
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jinjin WangDepartment of Nephrology, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, 310003, Zhejiang, People's Republic of China.
Tianmu ChenDepartment of Nephrology, Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine, Wenzhou, 325088, Zhejiang, People's Republic of China.
Yan FuThe Second School of Clinical Medicine, Hangzhou Normal University, Hangzhou, China.
Tianqi ZhuNanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, China.
Yaning FengSchool of Medical Technology and Information Engineering, Zhejiang Chinese Medical University, Hangzhou, China.
Yuxi FengDepartment of Nephrology, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, 310003, Zhejiang, People's Republic of China.
Xuan ZhangDepartment of Nephrology, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, 310003, Zhejiang, People's Republic of China.
Yi CaiThe First Clinical College, Zhejiang Chinese Medical University, Hangzhou, China.
Li GaoZhejiang Kangjing Hospital, Hangzhou, China.
Yongqiang LinDepartment of Nephrology, Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine, Wenzhou, 325088, Zhejiang, People's Republic of China. wzzxylinyongqiang@126.com.
Qinyang JinHeart Center, Department of Geriatrics, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, 310003, Zhejiang, People's Republic of China. jqy119@163.com.
Qin ZhuDepartment of Nephrology, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, 310003, Zhejiang, People's Republic of China. zhuqinfeifei@126.com.

Funding

Joint TCM Science & Technology Projects of National Demonstration Zones for Comprehensive TCM Reform GZY-KJS-ZJ-2026-090National Natural Science Foundation of China 82205008Research Project of the Zhejiang Province Natural Science Foundation LQ24H180007Zhejiang Provincial Administration of Traditional Chinese Medicine Project 2023ZF137Zhejiang Provincial Department of Health Project 2023RC242
6 · The paper itself

Abstract

IgA nephropathy (IgAN), the most common primary glomerular disease worldwide, poses challenges in predicting progression at diagnosis-particularly in primary care. This study developed and validated a model to estimate 5-year renal survival and support early risk stratification for personalized management. A total of 1135 patients with biopsy-confirmed IgAN from Hangzhou Hospital of Traditional Chinese Medicine (2014-2017) were retrospectively enrolled and randomly assigned to training and internal validation cohorts in a 7:3 ratio. An external validation cohort comprising 352 patients was obtained from three independent centers (2015-2020). To identify robust prognostic variables, 1000 bootstrap samples were generated from the training set, each subjected to tenfold cross-validation to determine the optimal regularization parameter (λ) for the LASSO-Cox model. Variables with non-zero coefficients were recorded across iterations, and the five most frequently selected were used to construct both the XGBoost survival model and a corresponding nomogram. Model performance was evaluated through discrimination, calibration, and clinical utility using ROC curves, Brier scores, calibration curve and decision curve analysis. The area under the curve (AUC) of the nomogram was 0.951 (95% CI, 0.914-0.988) in the training cohort and 0.927 (95% CI, 0.877-0.978) in the internal validation cohort. In the external validation cohort, the AUC was 0.913 (95% CI, 0.870-0.955). The Brier scores were 0.029 and 0.045 for the internal and external validation cohorts, respectively. DCA further demonstrated the favorable clinical utility of the nomogram. A clinically practical prognostic model incorporating routine clinical and pathological features was developed to estimate 5-year renal survival in patients with IgAN. Specifically designed for primary care settings, the model leverages easily accessible data to enable early identification of high-risk individuals and support personalized long-term management. Its simplicity and applicability in resource-limited environments make it a valuable tool for improving outcomes beyond specialist centers.

Indexed as

Glomerulonephritis, IGAAdultDisease ProgressionFemaleHumansMaleMiddle AgedNomogramsPrognosisRetrospective StudiesROC CurveFollow-up careIgA nephropathyInitial diagnosisMachine learning

Identifiers

PMID41392050
PMCPMC12819421

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.